Trapelo Health offers a cloud‑native, interoperable decision‑support platform that consolidates molecular‑testing evidence, guideline recommendations, and payer policies to suggest appropriate biomarker panels, accredited labs, and FDA‑cleared therapies for oncology patients. The solution automates test ordering, prior‑authorization submissions, and real‑time analytics through FHIR‑compliant APIs, enabling seamless EHR integration and faster, evidence‑based treatment and reimbursement decisions.
Funding
$4.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Oncologists, diagnostic labs, and payers face fragmented workflows and inconsistent evidence when selecting genomic tests and targeted therapies, leading to delayed treatment decisions and suboptimal reimbursement. The lack of real‑time data exchange makes it difficult to align testing orders, prior‑authorization requests, and clinical guidelines across stakeholders.
Solution
Trapelo Health delivers an interoperable, cloud‑native decision‑support platform that centralizes molecular‑testing evidence, guideline‑based recommendations, and payer policies. The system automatically suggests appropriate biomarker panels, preferred laboratories, and corresponding therapies based on a patient’s clinical profile. Integrated prior‑authorization workflows route requests to payers with pre‑populated justification, reducing turnaround time. Real‑time analytics surface utilization patterns and reimbursement eligibility, enabling value‑based care. The platform exposes standard FHIR APIs for seamless EHR integration, allowing clinicians to access recommendations within existing workflows. AI‑driven scoring continuously updates recommendations as new evidence emerges, ensuring clinicians receive the most current, evidence‑supported options at the point of care.
Target Audience
Primary users are oncologists and oncology practice groups, molecular diagnostic laboratories, and health‑plan payers seeking to streamline precision‑medicine workflows and improve reimbursement outcomes. Secondary users include pharmaceutical companies and clinical‑trial sponsors that require real‑time biomarker eligibility data.
Features
- Evidence‑based knowledge engine that maps tumor genomics to FDA‑cleared therapies, clinical trials, and guideline pathways (NCCN, ASCO).
- Automated test‑ordering assistant that ranks biomarker panels and selects optimal accredited labs based on coverage and turnaround metrics.
- Real‑time prior‑authorization engine with auto‑filled justification fields and status tracking, integrated via payer APIs.
- FHIR‑compliant interoperability layer for bidirectional data exchange with major EHRs (Epic, Cerner) and laboratory information systems.
- AI/ML recommendation engine that ingests new publications, FDA approvals, and payer policy updates to refresh clinical guidance daily.
- Dashboard and reporting suite delivering utilization analytics, cost‑impact modeling, and reimbursement eligibility alerts for health‑plan administrators.
- HIPAA‑grade encryption, role‑based access controls, and audit logging to meet regulatory compliance across all stakeholder groups.
- Clinical‑trial matching module that surfaces eligible studies based on molecular profile and geographic availability.